Welcome to the NETCancerAwarenessBlog’s first of the Speaker Spotlight Series-2016 National Conference Edition!!
Edward M. Wolin, MD
Director, Neuroendocrine Tumor Program, Montefiore Einstein Center for Cancer Care
Edward M. Wolin, MD is an internationally recognized Neuroendocrine Medical Oncologist. Patients from all over the United States and abroad come to see him for access to personalized care and the latest diagnostic and therapy programs.
Dr. Wolin graduated from Reed College in Portland, Oregon, and received his MD degree From Yale School of Medicine at Yale University in New Haven, Connecticut. After serving as intern and resident in Internal Medicine at Stanford University, he became a clinical fellow at the National Cancer Institute in Bethesda, Maryland. He returned to Stanford to complete his Fellowship in Medical Oncology before starting his academic career at the faculty of Washington University School of Medicine in St. Louis, Missouri.
Dr. Wolin was previously the Director of Neuroendocrine and GI Oncology Program and the Director of Clinical Research at the University of Kentucky Medical Center. For the preceding 26 years, he held key positions at Cedars–Sinai Medical Center in Los Angeles, where he founded and directed of one of the largest and most productive Carcinoid and Neuroendocrine Tumor Programs in the country.
Dr. Wolin treats all types of carcinoid and neuroendocrine tumors, ranging from tumors of the small intestine (carcinoid), pancreas, lung and colon to those of the rectum, appendix, stomach and other sites. These include hormone-producing tumors such as carcinoid (serotonin), gastrinoma (gastrin), insulinoma (insulin), glucagonoma (glucagon), VIPoma (VIP); liver metastasis, and carcinoid syndrome.
Dr. Wolin is a critical member of Montefiore’s outstanding multidisciplinary neuroendocrine team, that includes medical oncologists, surgeons, gastroenterologists, endocrinologists, as well as specialists in nuclear medicine, interventional radiology, diagnostic radiology, and other areas.
As Director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care, Dr. Wolin brings a robust research program to Montefiore that supports multiple clinical trials. His research efforts focus on finding the most effective and least toxic treatments, such as pasireotide, lanreotide, everolimus, other m-TOR inhibitors, targeted radiation, including peptide receptor radiotherapy with Lu-177.
Dr. Wolin has pioneered the development of neuroendocrine tumor therapy with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy (PRRT) using 177Lu-DOTATATE, as well as PET imaging with 67GA-DOTATATE scanning.
His research also pursues new directions in immunotherapy, anti-angiogenic drugs, novel targeted biologic anti-cancer treatments, as well as targeted treatment of liver metastases. In addition, Dr. Wolin directs his research towards the development of new imaging and diagnostic procedures for carcinoid/neuroendocrine tumors.
To make an appointment, please call:
Montefiore M-E Center for Cancer Center 1521 Jarrett Place Bronx, NY 10461-2601 (718) 862-8840
Dr. Wolin at the 2016 National NET Patient Conference:
Topic: The Role of Chemotherapy in Well-Differenciated NETs
When: Friday, September 23, 2016 at 2PM*
Be sure not to miss Dr. Wolin speak! And don’t miss him on our panel answering your questions!!
For additional info on Dr. Ed Wolin, please see his profile here.
If you would like to read some of Dr. Wolin’s pulications on PubMed, you can do so here.
SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. Wolin and 19 other experts speak on Neuroendocrine Cancer!
Registration is $125 per person including
- Thursday’s Welcome Reception
- Breakfast, Lunch, and snacks for both Friday and Saturday
- And keep your eyes out for some special prizes!
Registration does not include your hotel stay or travel expenses.
For more information and to buy your ticket, click here!!
*Time and Date are subject to change.